Fixed-dose combinations for emerging treatment of pain

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1261-1270

  Raffa, Robert B ^a   Tallarida, Ronald J ^b   Taylor, Robert ^c   Pergolizzi, Joseph V ^b,d,e  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEMA Research   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesic; Combination therapy; Fixed dose; Isobole; Pain

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ACETYLSALICYLIC ACID PLUS CAFFEINE PLUS DIHYDROCODEINE; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ASCOMP; BUPRENORPHINE PLUS NALOXONE; BUTALBITAL; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CAFFEINE; CARISOPRODOL; CHLORPHENIRAMINE MALEATE PLUS HYDROCODONE BITARTRATE PLUS PSEUDOEPHEDRINE; CHLORPHENIRAMINE POLISTIREX PLUS HYDROCODONE POLISTIREX; CODEINE; CODEINE PHOSPHATE PLUS GUAIFENESIN; CODEINE PHOSPHATE PLUS PHENYLEPHRINE PLUS PROMETHAZINE; DEXTROPROPOXYPHENE; EQUAGESIC; ESOMEPRAZOLE PLUS NAPROXEN; EXCEDRIN; FAMOTIDINE PLUS IBUPROFEN; HOMATROPINE METHYL BROMIDE PLUS HYDROCODONE BITARTRATE; HYCET; HYDROCHLOROTHIAZIDE PLUS METHYLDOPA; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROCODONE PLUS PSEUDOEPHEDRINE; IBUPROFEN; MORPHINE SULFATE PLUS NALTREXONE; NAPROXEN PLUS SUMATRIPTAN SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORGESIC; OPIATE; OXYCODONE PLUS PARACETAMOL; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PERCOCET; PROMETH; PROMETHAZINE; PROMETHAZINE VC; PROPACET; PROPACETAMOL; SYNALGOS; TAPENTADOL; TRAMADOL; TYLOX; UNCLASSIFIED DRUG;

ANALGESIA; CLINICAL EFFECTIVENESS; CONSTIPATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; NONHUMAN; PAIN; REVIEW; SIGNAL TRANSDUCTION;

EID: 84861401630     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.668531     Document Type: Review

References (71)

1. Gagliese L, Melzack R. Chronic pain in elderly people. Pain 1997;70(1):3-14
2. The management of persistent pain in older persons. AGS Panel on Persistent Pain in Older Persons. J Am Geriatr Soc 2002;50(6 Suppl):S205-24
3. Cavalieri TA. Pain management in the elderly. J Am Osteopath Assoc 2002;102(9):481-5
4. Covinsky KE, Lindquist K, Dunlop DD, et al. Pain, functional limitations, and aging. J Am Geriatr Soc 2009;57(9):1556-61
5. Ball MM, Perkins MM, Whittington FJ, et al. Managing decline in assisted living: the key to aging in place. J Gerontol B Psychol Sci Soc Sci 2004;59(4):S202-12
6. Hyde M, Wiggins RD, Higgs P, et al. A measure of quality of life in early old age: the theory, development and properties of a needs satisfaction model (CASP-19). Aging Ment Health 2003;7(3):186-94
7. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19(12):1985-91
8. Foley KM. How well is cancer pain treated? Palliat Med 2011;25(5):398-401
9. Breuer B, Fleishman SB, Cruciani RA, et al. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol 2011;29(36):4769-75
10. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8(4):287-313
11. Marchand S. The physiology of pain mechanisms: from the periphery to the brain. Rheum Dis Clin North Am 2008;34(2):285-309
12. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8(3):177-89
13. Lee SE, Kim JH. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. Neurosci Res 2007;58(3):245-9
14. Calvino B, Grilo RM. Central pain control. Joint Bone Spine 2006;73(1):10-16
15. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413(6852):203-10
16. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001;429(1-3):23-37
17. May A. Chronic pain may change the structure of the brain. Pain 2008;137(1):7-15
18. Hasenbring M. Attentional control of pain and the process of chronification. Prog Brain Res 2000;129:525-34
19. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288(5472):1765-9
20. Flor H, Nikolajsen L, Staehelin Jensen T. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006;7(11):873-81
21. Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain 1998;77(3):227-9
22. Backonja MM. Defining neuropathic pain. Anesth Analg 2003;97(3):785-90
23. Knudsen AK, Aass N, Fainsinger R, et al. Classification of pain in cancer patients-a systematic literature review. Palliat Med 2009;23(4):295-308
24. Lasheen W, Walsh D, Sarhill N, et al. Intermittent cancer pain: clinical importance and an updated cancer pain classification. Am J Hosp Palliat Care 2010;27(3):182-6
25. Marchand S. Applied Pain Neurophysiology. In: Beaulieu P, Lussier D, Porreca F, Dickenson AH, editors. Pharmacology of Pain. IASP Press; Seattle: 2010
26. Jensen KB, Kosek E, Petzke F, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009;144(1-2):95-100
27. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev 2004;27(8):729-37
28. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66(6):355-474
29. Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Brain Res Rev 2004;46(3):295-309
30. Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009;63(4):533-43
31. Terayama R, Dubner R, Ren K. The roles of NMDA receptor activation and nucleus reticularis gigantocellularis in the time-dependent changes in descending inhibition after inflammation. Pain 2002;97(1-2):171-81
32. Besson JM. The neurobiology of pain. Lancet 1999;353(9164):1610-15
33. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci 1994;15(6):190-7
34. Sutherland SP, Cook SP, McCleskey EW. Chemical mediators of pain due to tissue damage and ischemia. Prog Brain Res 2000;129:21-38
35. Pan HL, Wu ZZ, Zhou HY, et al. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther 2008;117(1):141-61
36. Dickenson AH. Central acute pain mechanisms. Ann Med 1995;27(2):223-7
37. Raffa RB, Pergolizzi JV, Segarnick DJ, et al. Oxycodone combinations for pain relief. Drugs Today (Barc) 2010;46(6):379-98
38. Podolsky SH, Greene JA. Combination drugs-hype, harm, and hope. N Engl J Med 2011;365(6):488-91
39. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12(6):804-13
40. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46(2):313-40
41. Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996(3):249-71
42. Hennies HH, Friderichs E, Wilsmann K, et al. Effect of the opioid analgesic tramadol on inactivation of norepinephrine and serotonin. Biochem Pharmacol 1982;31(8):1654-5
43. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260(1):275-85
44. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988;38(7):877-80
45. Lai J, Ma SW, Porreca F, et al. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 1996;316(2-3):369-72
46. Kayser V, Besson JM, Guilbaud G. Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat. Eur J Pharmacol 1992;224(1):83-8
47. Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol 1993;108(3):806-11
48. Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274(3):1263-70
49. Mimami K. Recent evidences in the pharmacological mechanisms of the tramadol. Masui 2005;54(11):1224-33
50. Li C, Chen SQ, Chen BX, et al. The antinociceptive effect of intrathecal tramadol in rats: the role of alpha 2-adrenoceptors in the spinal cord. J Anesth 2011; in press (as of 3/11/12)
51. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996;41(1):7-12
52. Sora I, Takahashi N, Funada M, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997;94(4):1544-9
53. Ide S, Minami M, Ishihara K, et al. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006;51(3):651-8
54. Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267(1):331-40
55. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci 1996;58(2):PL 23-8
56. Filitz J, Ihmsen H, Gunther W, et al. Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain 2008;136(3):262-70
57. Terlinden R, Kogel BY, Englberger W, et al. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32(1):31-8
58. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3- dimethylamino-1- ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/ norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323(1):265-76
59. Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14(8):814-21
60. Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337(1):312-20
61. Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, Phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31(2):260-71
62. Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, Phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25(3):765-76
63. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled Phase III study. Clin Drug Investig 2010;30(8):489-505
64. Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis. Chapman & Hall/CRC; Boca Raton: 2000
65. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003;307(2):699-704
66. Tallarida RJ, Raffa RB. The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther 2010;127(2):165-74
67. Tallarida RJ, Stone DJ Jr, McCary JD, et al. Response surface analysis of synergism between morphine and clonidine. J Pharmacol Exp Ther 1999;289(1):8-13
68. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3(6):285-90
69. Loewe S. Die Mischiarnei. Klin Wochenschr 1927;6:1077-85
70. Loewe S. Die quantitativen Probleme der Pharmakologie. Ergebn Physiol 1928;27:47-187
71. Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001;26(4):257-64